Eisai and Biogen look set to have a clear run at the Alzheimer’s disease market now that Roche’s rival candidate, gantenerumab, is out of the running after it failed in its two Phase III GRADUATE studies.
Gantenerumab did not significantly slow the progression of Alzheimer’s in the twin studies involving nearly 2,000 people with early disease.







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)